Search Results
611 Results Found for “drug development”
From AI and real-time toxicity monitoring to exercise and behavioural interventions, Prof Joanne Bowen explores the innovations reshaping supportive cancer care and outlines MASCC’s priorities for translating emerging evidence into meaningful improvements for patients.
Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.
Congress coverage | This May, experts from around the world gathered in Glasgow, Scotland for the the 7th SIOP Europe Annual Meeting. This year celebrated the importance of collaboration, bringing together the diverse stakeholders involved in facing children and adolescents with cancer, and ensuring all voices were heard. The Annual Meeting was held in partnership with CCI Europe, ensuring the representation and participation of childhood cancer parents and survivors.
At the 7th SIOP Europe Annual Meeting, emerging therapies, biological precision, and workforce development are all under the spotlight. Dr Daniela Di Carlo (Chair, Young SIOPE), reflects on where the field is heading, particularly CAR T-cell therapy and artificial intelligence, and what is needed to ensure that progress translates into real-world benefit for children with cancer.
At the 7th SIOP Europe Annual Meeting, Anita Kienesberger (Chair, Childhood Cancer International Europe [CCI Europe]), discusses the evolving landscape of paediatric oncology advocacy. She shares insights on the critical importance of psychosocial support, the necessity of collaborative research and the ongoing challenge of health inequalities across Europe. As CCI Europe transitions into an independent legal entity, Anita Kienesberger highlights the organisation's strategic shift toward empowering survivors and standardising long-term care.
Professor Pamela Kearns discusses the key points from her Plenary presentation on how the ITCC is expanding access to innovative therapies, harnessing precision data and reshaping Europe’s paediatric oncology clinical trial landscape. “We want to bring innovation directly to ...
At SIOPE 2026, discussions around early phase clinical development highlighted both the scientific advances and structural challenges shaping modern paediatric oncology. Prof Cornelis Van Tilburg is closely involved in both areas through his leadership of the clinical trials unit and multiple investigator-initiated studies in paediatric neuro-oncology. In this interview, he discusses the barriers affecting European early phase research, evolving paediatric trial methodologies, and the importance of international collaboration in precision oncology.
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Among glial tumours of the central nervous system (CNS), one of the most devastating is the category of H3K27-altered midline gliomas because of their uniform and rapid mortality, high neurological symptom burden and predilection for paediatric, adolescent and ...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
As part of our touchONCOLOGY Future Leaders 2026 programme, Dr Federico Monaca reflects on the mentors who shaped his approach to research and clinical trials, the importance of patience and patient-centred care, and the transformative potential of next-generation immunotherapies.
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
Emerging strategies in head and neck cancer focus on personalizing therapy and reducing toxicity. ctDNA-guided chemotherapy with pembrolizumab in recurrent HNSCC achieved a 73% response rate, while ozuriftamab vedotin showed promising activity in pretreated HPV-positive OPSCC. Long-term results from the Quarterback trials indicate that reduced-dose chemoradiation after induction chemotherapy maintains durable control in selected patients. These findings support further exploration of molecular-guided, targeted, and de-escalated approaches to optimize outcomes.
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
Breakthroughs from the 2025 San Antonio Breast Cancer Symposium in oral SERDs, HER2-targeted maintenance therapy, ADCs and next-generation endocrine combinations are reshaping breast cancer care across early and metastatic disease. From practice-changing phase III data to nuanced treatment selection in triple-positive and ESR1-mutant disease, this in-depth report unpacks what the latest trials really mean for clinicians. Register now to read the full analysis and stay ahead of rapidly evolving practice.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
